BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 18852012)

  • 21. Arylamine N-acetyltransferases--from drug metabolism and pharmacogenetics to identification of novel targets for pharmacological intervention.
    Sim E; Fakis G; Laurieri N; Boukouvala S
    Adv Pharmacol; 2012; 63():169-205. PubMed ID: 22776642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphic NATs and cancer predisposition.
    Hirvonen A
    IARC Sci Publ; 1999; (148):251-70. PubMed ID: 10493262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Irreversible inactivation of arylamine N-acetyltransferases in the presence of N-hydroxy-4-acetylaminobiphenyl: a comparison of human and hamster enzymes.
    Wang H; Wagner CR; Hanna PE
    Chem Res Toxicol; 2005 Feb; 18(2):183-97. PubMed ID: 15720122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3D model of human arylamine N-acetyltransferase 2: structural basis of the slow acetylator phenotype of the R64Q variant and analysis of the active-site loop.
    Rodrigues-Lima F; Dupret JM
    Biochem Biophys Res Commun; 2002 Feb; 291(1):116-23. PubMed ID: 11829470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Substrate selectivity of mouse N-acetyltransferases 1, 2, and 3 expressed in COS-1 cells.
    Estrada-Rodgers L; Levy GN; Weber WW
    Drug Metab Dispos; 1998 May; 26(5):502-5. PubMed ID: 9571233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NMR-based model reveals the structural determinants of mammalian arylamine N-acetyltransferase substrate specificity.
    Zhang N; Liu L; Liu F; Wagner CR; Hanna PE; Walters KJ
    J Mol Biol; 2006 Oct; 363(1):188-200. PubMed ID: 16959263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human N-acetylation of benzidine: role of NAT1 and NAT2.
    Zenser TV; Lakshmi VM; Rustan TD; Doll MA; Deitz AC; Davis BB; Hein DW
    Cancer Res; 1996 Sep; 56(17):3941-7. PubMed ID: 8752161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms.
    Hein DW; Doll MA; Fretland AJ; Leff MA; Webb SJ; Xiao GH; Devanaboyina US; Nangju NA; Feng Y
    Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):29-42. PubMed ID: 10667461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolizing enzyme arylamine N-acetyltransferase type 2 in mice.
    Boukouvala S; Price N; Plant KE; Sim E
    Biochem J; 2003 Nov; 375(Pt 3):593-602. PubMed ID: 12904181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacogenetics of NAT: structural aspects.
    Pompeo F; Brooke E; Kawamura A; Mushtaq A; Sim E
    Pharmacogenomics; 2002 Jan; 3(1):19-30. PubMed ID: 11966400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Arylamine N-acetyltransferase I.
    Minchin RF; Hanna PE; Dupret JM; Wagner CR; Rodrigues-Lima F; Butcher NJ
    Int J Biochem Cell Biol; 2007; 39(11):1999-2005. PubMed ID: 17392017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-acetyltransferase 2 polymorphism in patients with diabetes mellitus.
    Yalin S; Hatungil R; Tamer L; Ates NA; Dogruer N; Yildirim H; Karakas S; Atik U
    Cell Biochem Funct; 2007; 25(4):407-11. PubMed ID: 16397907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular and Functional Characterization of N-Acetyltransferases NAT1 and NAT2 in Cynomolgus Macaque.
    Uno Y; Murayama N; Yamazaki H
    Chem Res Toxicol; 2018 Nov; 31(11):1269-1276. PubMed ID: 30358977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction of Syrian hamster lines congenic at the polymorphic acetyltransferase locus (NAT2): acetylator genotype-dependent N- and O-acetylation of arylamine carcinogens.
    Hein DW; Doll MA; Rustan TD; Gray K; Ferguson RJ; Feng Y
    Toxicol Appl Pharmacol; 1994 Jan; 124(1):16-24. PubMed ID: 8291057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions.
    Hein DW; Doll MA; Rustan TD; Ferguson RJ
    Cancer Res; 1995 Aug; 55(16):3531-6. PubMed ID: 7627960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arylamine N-acetyltransferases.
    Sim E; Westwood I; Fullam E
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):169-84. PubMed ID: 17428149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis.
    Hein DW
    Mutat Res; 2002 Sep; 506-507():65-77. PubMed ID: 12351146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The xenobiotic-metabolizing enzymes arylamine N-acetyltransferases in human lens epithelial cells: inactivation by cellular oxidants and UVB-induced oxidative stress.
    Dairou J; Malecaze F; Dupret JM; Rodrigues-Lima F
    Mol Pharmacol; 2005 Apr; 67(4):1299-306. PubMed ID: 15644493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation.
    Liu F; Zhang N; Zhou X; Hanna PE; Wagner CR; Koepp DM; Walters KJ
    J Mol Biol; 2006 Aug; 361(3):482-92. PubMed ID: 16857211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-acetyltransferase 2 (Nat2) polymorphism in the sand rat Psammomys obesus.
    Khelil M; Djerdjouri B; Tayebi B
    Toxicol Mech Methods; 2010 Oct; 20(8):440-4. PubMed ID: 20550432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.